Nonplatinum‐based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population‐based Danish anal cancer group study

BACKGROUND: First‐line platinum‐based therapy for advanced squamous cell carcinomas of the anal canal (SCCA) implies a risk of substantial side effects, and data on second‐line treatment options are limited. Paclitaxel and Capecitabine are a well‐known regimen with a moderate toxicity profile, but i...

Descripción completa

Detalles Bibliográficos
Autores principales: Truelsen, Christina Glismand, Serup‐Hansen, Eva, Storm, Katrine Smedegaard, Havelund, Birgitte Mayland, Kronborg, Camilla Skovhus, Spindler, Karen‐Lise Garm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124117/
https://www.ncbi.nlm.nih.gov/pubmed/33960701
http://dx.doi.org/10.1002/cam4.3886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124117/
https://www.ncbi.nlm.nih.gov/pubmed/33960701
http://dx.doi.org/10.1002/cam4.3886

Ejemplares similares